1. Introduction {#sec1}
===============

Of the primary energy sources in the human body (carbohydrates, proteins, and lipids), lipids are the most efficient type of energy storage (9 kcal/g) and are hence much more prevalent than carbohydrates or proteins as a form of storage [@bib1]. This makes the process of lipid release a crucial component in understanding human energy metabolism and pathology. Several studies have reported that the incidence of metabolic syndrome in postmenopausal women is higher than in premenopausal women and that the causes are related not only to estrogen levels but also to the levels of other hormones related to lipid metabolism [@bib2].

The chronic override of free fatty acids (FFA) in the blood may be a risk factor in human energy metabolism. A high level of FFA often correlates with type 2 diabetes, hypertension, dyslipidemia, insulin resistance, hyper uric acid, and abnormal fibrinolysis [@bib3]. Obese individuals commonly show insulin resistance; correspondingly, their levels of fatty acids are also elevated. The most common cause of the positive correlations between FFA and several diseases is the competition between override FFA and carbohydrates in the energy oxidation process [@bib4]. Boden et al [@bib5] reported that after lipids were administered to test volunteers, lipid oxidation increased and carbohydrate oxidation decreased simultaneously. Compared to healthy volunteers, diabetic patients showed a 40--55% decrease in their insulin-stimulated glucose absorption rates [@bib6].

Energy metabolism differs between the postprandial and fasting states. In the postprandial state, carbohydrates are used as a major energy source and insulin is released. In the fasting state, adipocytes release triglycerides, which are broken down into FFA and glycerol, which then enter the circulatory system. During the overnight fasting period, the burst size of FFA during the daily cycle is maximized [@bib7].

In a fasting state, over the long term, basal metabolic lipolysis occurs when insulin levels and catecholamine levels decrease. In the short term, acute lipolysis occurs in "fight or flight" (emergency) states. In this state, catecholamines are triggered by the sympathetic nerve system [@bib8]. In cell membranes, those catecholamine signals stimulate β-adrenoreceptors, which activate adenylyl cyclase via simultaneous G-protein coupled receptors. Adenylyl cyclase then transforms adenosine triphosphate into cyclic adenosine monophosphate (cAMP). The cAMP then binds to the regulatory module of the protein kinase A, activating it, which then phosphates hormone-sensitive lipase (HSL) [@bib9].

Both long- and short-term lipolyses are affected by several hormones. Glucocorticoid [@bib10], adrenocorticotropic hormone (ACTH) [@bib11], thyroid hormone, dehydroepiandrosterone [@bib12], insulin [@bib7], and estrogen [@bib13] have all been shown to influence lipolysis through the functioning of β-adrenergic receptors, the production of adenylyl cyclase, the activities of G-proteins, or changes in cAMP production.

The lipolysis of white adipose tissue is influenced by the autonomic nervous system as well as the central nervous system. For example, when the sympathetic nerve directly stimulates the adrenal medulla, it causes catecholamine to be released. The catecholamine then stimulates adipocytes to trigger lipolysis. In addition to this catecholamine pathway, sympathetic nerves directly innervate within adipose tissue. Cousin et al [@bib14] reported that the level of lipids in the peritoneum increased after denervation. This suggests that the sympathetic nervous system influences the activity or differentiation of white adipose cells.

Parasympathetic nerves as well as sympathetic nerves showed a relation with adipose tissue. Kreier et al [@bib15] reported that when the parasympathetic nerve was removed, the HSL activity in white adipose tissue increased. However, the absorption of FFA and blood glucose decreased.

Given that the direct measurement of autonomic nervous activity by micrography is not feasible in a large epidemiological study, heart rate variability (HRV) is used as the measurement method for the autonomic nervous system [@bib16]. HRV is measured by the variation of the beat-to-beat interval. The average R-R is calculated by 60 divided by the average heart rate in beats/min. Chang et al [@bib17] showed that HRV is related to several component of metabolic syndrome (MtS). When they separated 1,298 individuals into four groups based on the components of MtS, those who had one or more components of MtS showed a lower standard deviation of the R-R interval compared to a healthy control group.

The recorded use of ginseng dates back 2,000 years. It has been one of the most popular herbal supplements in Asia, especially in Korea, China, and Japan. In the USA, ginseng ranked as one of the top-10 selling herbal supplements in 2003 [@bib18]. The primary effective components of ginseng are known as ginsenosides, and these include compound K (CK), Rg3, Rk1, and Rg5, all of which have a steroidal skeleton.

In the results of this study, CK served as the ligand of glucocorticoid receptor (GR) [@bib19] and Rg3 functioned as the ligand of estrogen receptor (ER) [@bib20], which implies a possible effect of ginseng on lipolysis. In fact, when CK was administered to a 3T3-L1 adipocyte cell line, the storage of triglycerides was suppressed. On the other By contrast, Rg1 stimulated triglyceride storage in adipocytes [@bib21]. Rg3, Rk1, and Rg5 treatments in 3T3-L1 suppressed lipid accumulation [@bib22].

As well as the reported effects of ginseng on FFA, red ginseng has also been shown to have a beneficial effect on insulin and glucose regulation. Vuksan et al [@bib23] reported that red ginseng consumption improved insulin and glucose regulation in type 2 diabetes patients. Lee et al [@bib24] showed that red ginseng has a beneficial effect on insulin sensitivity. We also reported that fermented red ginseng (FRG) showed a serial causal effect on the level of hormones, insulin resistance, and insulin levels. In an analysis of the effects of hormones on glucose blood levels, the difference between the FRG group and the placebo group was due to the level of aldosterone [@bib25].

According to an experiment with mice, ginsenosides stimulated an acetylcholine release in the terminal of cholinergic neurons [@bib26]. In a human study with 120 adult men, wild ginseng increased the activity of the autonomic nerves and increased the heart rate [@bib27].

The first aim of this study was to test the hypothesis that hormones (including insulin) and the branchial pulse rate (the autonomic nervous system activity) affected the flux of FFA in the blood. For this analysis, a path model was established and estimates of the model fit and the hypothesis were then tested. The second aim of this study was to test whether FRG consumption affects the relationship between the independent variables of several hormones and the autonomic nervous system and the dependent variable of FFA.

The study hypotheses were: (1) ACTH, growth hormone (GH), E2, glucocorticoid, tri-iodothyronine (T3), thyroid-stimulating hormone, and/or insulin influence the release of FFA; (2) the brachial pulse rate, which represents the activity of the autonomic nervous system and affects the release of FFA from adipocytes; and (3) the consumption of FRG changes the rate of FFA release, and this release is mediated by FRG on ER or GR.

2. Materials and methods {#sec2}
========================

2.1. Participants and study design {#sec2.1}
----------------------------------

This study was approved by the Institutional Review Board of Sahmyook University (Seoul, Korea). The study participants were 117 postmenopausal women (age 50--73 yr) who were recruited from four Catholic churches. Participants with any disease, including diabetes, cardiovascular disease, dyslipidemia, and kidney disease, were excluded. None of the study participants took any supplements for 2 wk prior to or during the experiment.

Anthropometric parameters were used to evaluate and categorize the 117 participants, who then had their brachial and ankle blood pressure and brachial and ankle blood pulse measured twice, once in the supine position and again after a 10-min rest period. Although the brachial and ankle pressures and pulse rate vary according to the spectrum of life activity, the pressure and the pulse in the supine position can be considered as the pressure and the pulse of a participant in a resting state.

After overnight fasting, blood and urine samples from the 117 participants were collected from 8:00 [am]{.smallcaps} to 10:00 [am]{.smallcaps}. The study participants were then divided into two groups according to the double-blind method of drawing lots. One group was supplied with capsules containing FRG powder (Bifido Inc., Gangwon-do, Korea), and the other group was supplied with placebo capsules containing edible starch for 2 wk. Because a hypothesis of this study was that ginsenosides are ligands of nuclear receptors and that the effects of a nuclear receptor can begin within 2 h, we considered that 2 wk of FRG consumption was sufficient.

The ingredients of the FRG capsules were as follows: crude saponin, 258.6 mg/g; compound K, 57.05 mg/g; Rg3, 53.85 mg/g; Rh2, 11.97 mg/g; Rg2, 5.72 mg/g; Rh1, 2.99 mg/g; and Rb1, 0.023 mg/g. The total weight of the FRG capsule powder was 2.1 g. After 2 wk, 24 women dropped out of the study; therefore, 93 women (49 in the FRG group and 45 in the placebo group) participated in the second blood sample collection. The reported cause of departure for 23 of the women was individual personal reasons not related to FRG consumption. One woman left the experiment after reporting insomnia associated with her consumption of FRG ([Fig. 1](#fig1){ref-type="fig"}).

Blood samples were measured at the Green Cross Reference Laboratory (Gyeonggi-do, Korea). The methods of sample analysis are listed in [Appendix I](#appsec1){ref-type="sec"}.

Blood samples from 20 women/group were further collected and matched according to age, height, weight, and body mass index.

2.2. Statistical analyses {#sec2.2}
-------------------------

The arithmetic means of the variables from both groups were analyzed by SPSS version 18.0 (SPSS Inc., Chicago, IL, USA). The outliers of insulin and E2 were excluded and considered as missing values. Unmeasured variables were considered as random missing values and 10 datasets were generated by a multiple imputation method [@bib28].

Path analysis has several advantages in that several variables and multiple groups can be analyzed simultaneously; moreover, the effects of decomposition and model fitness can be assessed. We used path analysis as well as traditional statistics including mean comparisons in this study. The path model was analyzed with Mplus 6.11 (Muthén & Muthén, Los Angeles, CA, USA). The data in this report are part of an FRG study that was conducted in Seoul, Korea in 2010. Only the data relevant to this analysis are presented in this report.

3. Results {#sec3}
==========

3.1. Anthropometric data {#sec3.1}
------------------------

There were no significant differences in age, weight, height, and body mass index between the FRG group and the placebo group ([Table 1](#tbl1){ref-type="table"}).

3.2. Arithmetic mean comparisons {#sec3.2}
--------------------------------

Hormones showed circadian variation and seasonal variation. Despite the fact that a double-blind random sampling method was utilized in this study, there was sampling error. Therefore, the analyses of the hormones and other variables required crosstalk validation and a comprehensive assessment. We analyzed the mean comparisons of samples between the FRG group and the placebo group with three statistical methods: an analysis of covariance (ANCOVA) in the second samples (ANCOVA comparison), independent *t* tests of the second samples (second sample *t* test), and independent *t* tests of the differences between the second and first samples (difference *t* test; [Table 2](#tbl2){ref-type="table"}). In the ANCOVA comparison, the mean values of ACTH, cortisol, T3, and FFA did not show a significant difference between the two groups, whereas the level of insulin was lower in the FRG group than it was in the placebo group (*p* = 0.04). In the difference *t* test, the level of insulin was found to be lower in the FRG group than in the placebo group (*p* = 0.01). In the ANCOVA comparison, the level of dehydroepiandrosterone was higher in the FRG group than it was in the placebo group (*p* = 0.05), and the same result was shown in the difference *t* test (*p* = 0.03). In the ANCOVA comparison, the levels of E2 (*p* = 0.06) and GH (*p* = 0.06) were higher in the FRG group than in the placebo group, but the differences were not statistically significant ([Table 2](#tbl2){ref-type="table"}).

3.3. Path model {#sec3.3}
---------------

The baseline model was established based on reports in the literature. The Wald test was conducted to test the hypothesis of whether or not there was a significant difference between groups for each path. The path of cortisol on FFA and the path of the brachial pulse rate on FFA both showed a significant difference between the two groups ([Table 3](#tbl3){ref-type="table"}).

The final model was then established ([Fig. 2](#fig2){ref-type="fig"} and [Table 4](#tbl4){ref-type="table"}). The path of cortisol on FFA and the path of the brachial pulse rate on FFA were measured freely, whereas the other paths were analyzed with equality constraints ([Fig. 2](#fig2){ref-type="fig"}). Therefore, the values of the unstandardized coefficients of the path of cortisol on FFA and the values of the unstandardized coefficients of the path of the brachial pulse rate on FFA were two in both cases, and the values of the other unstandardized coefficients were one ([Fig. 2](#fig2){ref-type="fig"}). The final model\'s goodness of fit was good, as the root mean square error of approximation was 0.000 and the comparative fit index was 1.000.

When the effects of several independent variables on the FFA levels were compared with standardized coefficients, the path coefficients of E2 on FFA were highest at 0.678 in the FRG group and 0.656 in the placebo group.

The standardized coefficients of cortisol on FFA were 0.387 in the placebo group, whereas it was −0.233 in the FRG group. Therefore, when cortisol increased by a standardized deviation (3.5 μg/dL), the level of FFA increased by 0.387 standard deviations (0.387 × 232.1 μEq/L = 89.8 μEq/L) in the placebo group, whereas when cortisol increased by a standardized deviation (3.8 μg/dL), the level of FFA decreased by 0.233 standard deviations (0.233 × 217.0 μEq/L = 50.6 μEq/L) in the FRG group ([Table 4](#tbl4){ref-type="table"}).

Squared multiple correlation (SMC; $\text{R}_{\text{smc}}^{2}$) refers to the square value of the standardized estimate and SMC signifies the explanation ability of the independent variables on the fluctuation of the dependent variables. For example, the standardized estimate of the brachial pulse rate on FFA was 0.081 and the SMC of the brachial rate on FFA was 0.01 (1% = 0.081^2^) in the placebo group, whereas in the FRG group the estimate of the brachial pulse rate on FFA was 0.464 and the SMC of the brachial rate on FFA was 0.215 (21.5% = 0.464^2^). The standardized estimates of ACTH on FFA and T3 on FFA were both below 0.1, demonstrating no significant influence on the concentration of FFA in the final model ([Table 4](#tbl4){ref-type="table"}).

The SMC values of FFA were 0.699 (*p* \< 0.01) in the placebo group and 0.707 (*p* \< 0.01) in the FRG group. When the brachial pulse variable was excluded from the final model, the SMC of FFA changed to 0.671, which did not show a significant change in the placebo group. However, the SMC of FFA in the FRG group decreased by 0.500, which implies the importance of the brachial pulse rate on FFA release in the FRG group.

4. Discussion {#sec4}
=============

4.1. E2 and FFA {#sec4.1}
---------------

The accumulation pattern for postmenopausal women is different from that for men [@bib29]. In females, the major locations of fat accumulation are in the lower body and in subcutaneous tissue, whereas in males fat accumulates in the upper body and in the organs of the abdominal cavity (visceral fat). The fat accumulation area is important in relation to the onset of MtS [@bib30] because released FFA from abdominal adipocytes are directly transported to the liver via the hepatic portal vein, resulting in a decrease in insulin clearance and an increase in the synthesis of triglycerides and very low density lipoprotein [@bib31]. Therefore, the movement and accumulation effect of lipids by E2 are important for a proper understanding of the lipid metabolic process.

The effects of E2 on lipolysis are different between subcutaneous adipocytes and abdominal adipocytes. For example, E2 treatment decreased the level of lipolysis in the adipocytes, which mediated an increased number of α2A--adrenergic receptors, whereas E2 treatment did not show any effect on the lipolysis of the abdominal adipocytes [@bib32]. In addition, abdominal adipocytes showed a low level of α-adrenoreceptors and a high level of β-adrenoreceptors when compared to the level of β-adrenoreceptors in subcutaneous adipocytes [@bib33]. These differences in the ratio with regard to the adrenoreceptor type may help to explain differences in gender-dependent spatial fat accumulation.

In the present study, the positive relationship between the concentrations of E2 and FFA may have been due to the fasting times and the lowered E2 levels of the postmenopausal women in the present study design. Because blood samples were collected after 8 h of overnight fasting, the migration effect of FFA by lipoprotein lipase from the circulatory system to the adipocytes can be ignored. However, it was possible to infer that genome independent lipolysis by E2 could stimulate HSL and inositol triphosphate activities. Even though it is well known that Rg3 acts as the ligand of ERs and Rg3 was a high ratio of ginsenosides in this study, the effect of E2 on FFA did not show a significant difference between the groups.

4.2. Cortisol and FFA {#sec4.2}
---------------------

Djurhuus et al [@bib34] reported that when a physiologically high level of cortisol was injected into the adipose tissue, the level of blood FFA increased by 60%, as mediated by lipolysis stimulation. In the final model here, the path coefficient value of cortisol on FFA was positive (*p* = 0.002) in the placebo group, whereas the path coefficient value was negative (*p* *=* 0.082) in the FRG group. Therefore, it may be presumed that CK consumption acts as a competitive inhibitor with cortisol of the GR in this study.

In a postprandial state, insulin is released and suppresses the functions of HSL and lipolysis in adipocytes. In a fasting state, however, the level of insulin decreases, and the levels of cortisol and growth hormone increase, which in turn stimulates the expression of HSL [@bib35]. The proper expression of HSL is important in the regulation of blood glucose. HSL-deficient mice cannot release a proper level of FFA and thus enter into an insulin-resistant state [@bib36]. However, in the present study, the growth hormone and FFA showed a significant negative relationship. These results may be due to the decreased level of GH of the postmenopausal women owing to the natural process of aging. In fact, the explanation ability levels (SMC) of GH on the FFA concentration results were only 1% in the placebo group and 2% in the FRG group.

4.3. Brachial pulse rate and FFA {#sec4.3}
--------------------------------

Although several studies have reported that the activity of the sympathetic nervous system is related to MtS [@bib17; @bib37], the exact mechanism of this has yet to be elucidated. Jeon et al [@bib38] reported that when crude saponin, including ginsenoside, was intravenously injected into rats, their heart rates increased. Because GR and ER are present in the brain stem area, it may be presumed that CK and Rg3, ligands of GR and ER, regulate the autonomic nervous system via the central nervous system. Therefore, consecutively, brain stems that have GR and ER influenced by CK and Rg3 could have an effect on how FFA is released in adipocytes. If so, it would be of interest to assess whether CK or Rg3 has the strongest effect on the brachial pulse rate in this study. ER-α is present in the autonomic nerve center of the brain stem, which regulates the cardiovascular system [@bib38]. When estrogen was administered into this area, autonomic nerve regulation of the heart improved and the level of sympathetic activity decreased [@bib39]. Furthermore, when estrogen was injected into the brain of an ovariectomized rat, its heart rate decreased [@bib40].

GR is highly expressed in the dorsal hindbrain area and is especially prominent in the nucleus of the solitary tract [@bib41]. These areas are centers of cardiovascular regulation. When cortisol was injected into the dorsal hindbrain of a rat, its heart rate increased within 3 days [@bib42]. Therefore, because the autonomic effect on FFA was increased in the FRG group, CK was shown to have a stronger effect in the FRG group as compared to the placebo group.

4.4. Counteraction between cortisol and the brachial pulse {#sec4.4}
----------------------------------------------------------

In the final path model ([Fig. 2](#fig2){ref-type="fig"} and [Table 4](#tbl4){ref-type="table"}), two paths showed significant differences between two groups, and the significance levels were changed between the two paths and two groups. In this case, the significance levels of the path coefficients of cortisol to FFA were significant in the placebo group (*p* = 0.002) but were not significant in the FRG group (*p* = 0.082). However, the significant level of the brachial pulse on the FFA path was not significant in the placebo group (*p* = 0.428), although it was significant in the FRG group (*p* \< 0.001). These results may help researchers establish the homeostasis levels of essential components such as the major energy source, FFA, in human physiology.

In the change of significance levels, one possible cause of the "rise and fall" phenomenon between the two groups is the nature of the glucocorticoid receptors (GR). GRs can be influenced by genetic variations, redundancies, synergy, crosstalk with other nuclear receptors, and by other types of cell signaling. Therefore, in the path of cortisol to FFA, some test participants showed a significant effect of FRG consumption, whereas others did not show a strong effect. However, for the complimentary path of cortisol to FFA, the path of the brachial pulse rate to the FFA level showed that the "rise and fall" phenomenon or the "seesaw" phenomenon between the cortisol level and the brachial pulse rate was related to the homeostasis of FFA.

Regarding the methodology, these results are good examples that show that path analysis may be a useful tool for the simultaneous analysis and comparison of the effects of several independent variables on dependent variables with multiple groups.

5. Conclusions {#sec5}
==============

Among the several variables in this study, estrogen best explained FFA fluctuations. The brachial pulse provided a better explanation of FFA variance in the FRG group than in the placebo group. Cortisol had a strong effect on FFA release in the placebo group, but it did not have this effect in the FRG group. These "seesaw" effects between the brachial pulse rate and cortisol imply multiple routes of human physiology as regards the homeostasis of FFA. In conclusion, FRG consumption changed the effect of cortisol on FFA levels from peripheral tissues to the autonomic nervous system, whereas the level of FFA and the effects of other variables on FFA remained unchanged.

The effect of ginsenosides on human physiology depends on the ratio, dose, and treatment period of the ginsenosides. A study with a single type of ginsenoside in different environments would improve our understanding of the effects of hormones on FFA levels.
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![Flow of this study. The 117 volunteers who participated in the first blood sample collection were divided into two groups with random double-blind trials. The blood samples were collected between 8:00 [am]{.smallcaps} and 10:00 [am]{.smallcaps}. One group took fermented red ginseng (FRG) capsules three times/day (2.1 g/d) for 2 wk. The other group took a placebo containing starch. Ninety-three women participated in the second blood sample collection. Ninety of the 93 participants were postmenopausal, and three were perimenopausal.](gr1){#fig1}

![The equality constrained final model. The path of cortisol on free fatty acid (FFA) and the path of brachial pulse rate on FFA were freely analyzed and the other paths were constrained for equality between the fermented red ginseng (FRG) group and the placebo group. The numbers on the arrow line represent the unstandardized estimates of path. ACTH, adrenocorticotropic hormone; CFI, comparative fit index, DHEAS, dehydroepiandrosterone; FFA, free fatty acid; FSH, follicle stimulating hormone; GH, growth hormone; LH, luteinizing hormone; R^2^, squared multiple correlations (SMC); RMSEA, root mean square error of approximation; T3, tri-iodothyronine; TSH, thyroid-stimulating hormone.](gr2){#fig2}

###### 

Anthropometric Data of Participants

                             Mean ± SD      *p*            
  -------------------------- -------------- -------------- -------
  Age (yr)                   58.5 ± 5.5     58.6 ± 5.8     0.944
  Weight (kg)                56.9 ± 6.7     57.7 ± 6.9     0.559
  Height (cm)                157.7 ± 5.3    156.6 ± 5.4    0.311
  BMI (kg/m^2^)              22.88 ± 2.39   23.55 ± 2.51   0.189
  Waist circumference (cm)   32.7 ± 2.3     33.1 ± 2.4     0.397
  Hip circumference (cm)     36.9 ± 2.0     37.3 ± 2.1     0.284
  Waist/hip                  0.89 ± 0.03    0.89 ± 0.04    0.965

BMI, body mass index; FRG, fermented red ginseng; SD, standard deviation.

###### 

Comparison of Hormones and Free Fatty Acid Between the Fermented Red Ginseng (FRG) Group and the Placebo Group

  Markers                           Sample               Groups               Mean ± SD (*n*)      *p*[1)](#tbl2fn1){ref-type="table-fn"} (*p*[2)](#tbl2fn2){ref-type="table-fn"})   Δ2^nd^ -- 1^st^   
  --------------------------------- -------------------- -------------------- -------------------- --------------------------------------------------------------------------------- ----------------- --
  ACTH (pg/mL)                      1^st^                Placebo              19.6 ± 10.1 (43)     0.712                                                                                               
  FRG                               20.6 ± 13.2 (49)                                                                                                                                                   
  2^nd^                             Placebo              20.4 ± 10.1 (44)     0.321                2.3 (43)                                                                          0.52              
  FRG                               22.7 ± 11.8 (49)     (0.34)               0.9 (49)                                                                                                                 
  Cortisol (μg/dL)                  1^st^                Placebo              11.4 ± 3.3 (43)      0.064                                                                                               
  FRG                               9.9 ± 4.2 (49)                                                                                                                                                     
  2^nd^                             Placebo              11.2 ± 3.5 (44)      0.531                −0.2 (43)                                                                         0.13              
  FRG                               10.8 ± 3.8 (49)      (0.52)               0.9 (49)                                                                                                                 
  Estradiol (pg/mL)                 1^st^                Placebo              22.6 ± 17.3 (20)     0.693                                                                                               
  FRG                               20.6 ± 15.1 (20)                                                                                                                                                   
  2^nd^                             Placebo              14.5 ± 7.3 (19)      0.083                −7.4 (19)                                                                         0.06\*            
  FRG                               18.3 ± 7.3 (19)      (0.06\*)             1.0 (19)                                                                                                                 
  GH (ng/mL)                        1^st^                Placebo              1.4 ± 1.3 (20)       0.424                                                                                               
  FRG                               1.9 ± 2.6 (20)                                                                                                                                                     
  2^nd^                             Placebo              0.9 ± 1.2 (20)                            −0.40 (20)                                                                        0.50              
  FRG                               1.8 ± 1.4 (20)       (0.06\*)             −0.06 (20)                                                                                                               
  DHEAS (μg/dL)                     1^st^                Placebo              71.5 ± 28.9 (43)     0.412                                                                                               
  FRG                               66.7 ± 26.8 (49)                                                                                                                                                   
  2^nd^                             Placebo              65.2 ± 31.4 (44)     0.871                −6.2 (43)                                                                         0.03\*\*          
  FRG                               66.2 ± 29.1(49)      (0.05\*)             0.5 (49)                                                                                                                 
  Insulin (μU/mL)                   1^st^                Placebo              6.5 ± 7.2 (43)       0.667                                                                                               
  FRG                               7.1 ± 6.2 (49)                                                                                                                                                     
  2^nd^                             Placebo              6.4 ± 3.6 (43)       0.838                1.0 (43)                                                                          0.01\*\*          
  FRG                               6.3 ± 2.9 (48)       (0.04\*\*)           −0.2 (48)                                                                                                                
  Glucose (mg/dL)                   1^st^                Placebo              91.9 ± 8.9 (43)      0.211                                                                                               
  FRG                               89.9 ± 6.8 (49)                                                                                                                                                    
  2^nd^                             Placebo              89.6 ± 6.8 (44)      0.128                2.2 (43)                                                                          0.85              
  FRG                               87.4 ± 7.1 (49)      (0.31)               2.5 (49)                                                                                                                 
  FSH (mIU/mL)                      1^st^                Placebo              73.8 ± 25.6 (20)     0.261                                                                                               
  FRG                               65.6 ± 19.6 (20)                                                                                                                                                   
  2^nd^                             Placebo              74.0 ± 24.3 (20)     0.387                0.1 (20)                                                                          0.44              
  FRG                               68.0 ± 18.5 (20)     (0.68)               2.4 (20)                                                                                                                 
  LH (mIU/mL)                       1^st^                Placebo              37.8 ± 14.7 (20)     0.068\*                                                                                             
  FRG                               30.6 ± 8.8 (20)                                                                                                                                                    
  2^nd^                             Placebo              38.8 ± 14.8 (20)     0.036\*\*            1.0 (20)                                                                          0.56              
  FRG                               30.3 ± 9.0 (20)      (0.30)               −0.3 (20)                                                                                                                
  TSH (μIU/mL)                      1^st^                Placebo              2.7 ± 1.6 (20)       0.058\*                                                                                             
  FRG                               1.9 ± 1.0 (20)                                                                                                                                                     
  2^nd^                             Placebo              2.8 ± 1.8 (20)       0.298                0.1 (20)                                                                          0.41              
  FRG                               2.3 ± 1.2 (20)       (0.80)               0.4 (20)                                                                                                                 
  T3 (pg/dL)                        1^st^                Placebo              ---                                                                                                                      
  FRG                               ---                                                                                                                                                                
  2^nd^                             Placebo              912.1 ± 912 (20)                          0.12 (20)                                                                         0.33              
  FRG                               935.6 ± 123 (20)     (0.86)               0.06 (20)                                                                                                                
  FFA (μEq/L)                       1^st^                Placebo              662.4 ± 232.1 (43)   0.901                                                                                               
  FRG                               656.8 ± 197.3 (49)                                                                                                                                                 
  2^nd^                             Placebo              640.0 ± 223.7 (44)   0.653                −23.5 (43)                                                                        0.61              
  FRG                               660.3 ± 217.0 (49)   (0.61)               3.8 (49)                                                                                                                 
  Brachial Pulse rate (beats/min)   1^st^                Placebo              70.1 ± 8.4 (48)      0.654                                                                                               
  FRG                               69.4 ± 9.5 (44)                                                                                                                                                    
  2^nd^                             Placebo              68.5 ± 8.5 (48)      0.957                −0.6 (47)                                                                         0.494             
  FRG                               68.4 ± 8.5 (43)      (0.829)              −1.7 (44)                                                                                                                

\* *p* \< 0.1.

\*\* *p* \< 0.05.

\*\*\* *p* \< 0.01.

Δ2^nd^ -- 1^st^, second sample minus first sample; (*n*), number of samples; ACTH, adrenocorticotropic hormone; DHEAS, dehydroepiandrosterone; FSH, follicle stimulating hormone; GH, growth hormone; LH, luteinizing hormone; SD, standard deviation; T3, tri-iodothyronine; TSH, thyroid-stimulating hormone.

Independent *t* test.

Analysis of covariance.

###### 

Path Coefficients of Baseline Model and the Values of Wald Test

  Path                  Group                 Unstandardized estimate   Standardized estimate   Wald test              
  --------------------- --------------------- ------------------------- ----------------------- ---------------------- --------------
  ACTH                  Cortisol              FRG                       0.448 ± 0.096\*\*\*     0.556 ± 0.099\*\*\*    0.056
  Placebo               0.413 ± 0.114\*\*\*   0.479 ± 0.116\*\*\*                                                      
  TSH                   T3                    FRG                       0.537 ± 0.202 \*\*\*    0.475 ± 0.168\*\*\*    2.566
  Placebo               0.135 ± 0.119         0.217 ± 0.194                                                            
  FSH                   LH                    FRG                       0.610 ± 0.216\*\*\*     0.506 ± 0.135\*\*\*    0.712
  Placebo               0.920 ± 0.269\*\*\*   0.600 ± 0.128\*\*\*                                                      
  FSH                   Estradiol             FRG                       −0.473 ± 0.309          −0.311 ± 0.195         0.091
  Placebo               −0.328 ± 0.498        −0.252 ± 0.359                                                           
  LH                    Estradiol             FRG                       −0.208 ± 0.243          −0.160 ± 0.184         0.631
  Placebo               0.102 ± 0.255         0.125 ± 0.271                                                            
  Insulin               FFA                   FRG                       −0.347 ± 0.114\*\*\*    −0.338 ± 0.101\*\*\*   2.644
  Placebo               −0.007 ± 0.158        −0.007 ± 0.132                                                           
  Cortisol              FFA                   FRG                       −0.253 ± 0.144\*        −0.250 ± 0.140\*       10.133\*\*\*
  Placebo               0.457 ± 0.152\*\*\*   0.386 ± 0.127\*\*\*                                                      
  Estradiol             FFA                   FRG                       0.865 ± 0.153\*\*\*     0.701 ± 0.106\*\*\*    0.095
  Placebo               0.795 ± 0.165\*\*\*   0.667 ± 0.107\*\*\*                                                      
  GH                    FFA                   FRG                       −0.347 ± 0.186\*\*      −0.298 ± 0.141\*\*     3.304\*
  Placebo               0.144 ± 0.234         0.088 ± 0.140                                                            
  ACTH                  FFA                   FRG                       0.068 ± 0.111           0.085 ± 0.139          0.452
  Placebo               0.181 ± 0.128         0.177 ± 0.125                                                            
  T3                    FFA                   FRG                       0.056 ± 0.291           −0.032 ± 0.178         0.188
  Placebo               0.086 ± 0.273         0.037 ± 0.114                                                            
  DHEAS                 FFA                   FRG                       0.296 ± 0.108\*\*\*     0.240 ± 0.097\*\*      2.287
  Placebo               −0.016 ± 0.160        −0.016 ± 0.128                                                           
  TSH                   FFA                   FRG                       −0.370 ± 0.282          −0.206 ± 0.165         3.147\*
  Placebo               0.196 ± 0.241         0.132 ± 0.168                                                            
  Brachial Pulse rate   FFA                   FRG                       0.677 ± 0.199\*\*\*     0.462 ± 0.110\*\*\*    5.152\*
  Placebo               0.107 ± 0.168         0.071 ± 0.111                                                            
  SMC of FFA                                  FRG                                               0.760\*\*\*            
                        Placebo                                         0.733\*\*\*                                    

\* *p* \< 0.1.

\*\* *p* \< 0.05.

\*\*\* *p* \< 0.01.

ACTH, adrenocorticotropic hormone; DHEAS, Dehydroepiandrosterone; FFA, free fatty acid; FRG, fermented red ginseng; FSH, follicle stimulating hormone; GH, growth hormone; LH, luteinizing hormone; SMC, squared multiple correlations ($\text{R}_{\text{smc}}^{2}$); T3, tri-iodothyronine; TSH, thyroid-stimulating hormone.

###### 

Path Coefficients of Equality Constrained Final Model

  Path                  Group                 Unstandardized estimate   Standardized estimate                                               
  --------------------- --------------------- ------------------------- ----------------------- --------------------- --------------------- ---------
  ACTH                  GC                    Placebo                   0.433 ± 0.073\*\*\*     0.000                 0.497 ± 0.084\*\*\*   \<0.001
  FRG                   0.543 ± 0.085\*\*\*   \<0.001                                                                                       
  TSH                   T3                    Placebo                   0.267 ± 0.117\*\*       0.022                 0.383 ± 0.135\*\*\*   0.005
  FRG                   0.255 ± 0.134\*\*     0.057                                                                                         
  FSH                   LH                    Placebo                   0.722 ± 0.164\*\*\*     0.000                 0.504 ± 0.105\*\*\*   \<0.001
  FRG                   0.568 ± 0.105\*\*\*   \<0.001                                                                                       
  FSH                   E2                    Placebo                   −0.398 ± 0.329          0.227                 −0.291 ± 0.242        0.230
  FRG                   −0.276 ± 0.230        0.230                                                                                         
  LH                    E2                    Placebo                   −0.007 ± 0.164          0.968                 −0.002 ± 0.165        0.989
  FRG                   −0.006 ± 0.142        0.967                                                                                         
  Insulin               FFA                   Placebo                   −0.245 ± 0.096\*        0.011                 −0.188 ± 0.074\*      0.011
  FRG                   −0.250 ± 0.097\*      0.010                                                                                         
  GC                    FFA                   Placebo                   0.494 ± 0.163\*\*\*     0.002                 0.387 ± 0.114\*\*\*   0.001
  FRG                   −0.229 ± 0.132\*      0.082                     −0.233 ± 0.135\*        0.083                                       
  E2                    FFA                   Placebo                   0.824 ± 0.102\*\*\*     0.000                 0.656 ± 0.078\*\*\*   \<0.001
  FRG                   0.678 ± 0.081\*\*\*   \<0.001                                                                                       
  GH                    FFA                   Placebo                   −0.211 ± 0.169          0.213                 −0.108 ± 0.087        0.215
  FRG                   −0.188 ± 0.146        0.197                                                                                         
  ACTH                  FFA                   Placebo                   0.061 ± 0.085           0.471                 0.053 ± 0.077         0.485
  FRG                   0.079 ± 0.110         0.469                                                                                         
  T3                    FFA                   Placebo                   0.002 ± 0.209           0.994                 0.002 ± 0.090         0.980
  FRG                   0.000 ± 0.125         0.997                                                                                         
  DHEAS                 FFA                   Placebo                   0.155 ± 0.104           0.136                 0.114 ± 0.077         0.136
  FRG                   0.131 ± 0.091         0.151                                                                                         
  TSH                   FFA                   Placebo                   −0.197 ± 0.184          0.286                 −0.122 ± 0.117        0.297
  FRG                   −0.112 ± 0.107        0.294                                                                                         
  Brachial Pulse rate   FFA                   Placebo                   0.135 ± 0.171           0.428                 0.081 ± 0.101         0.423
  FRG                   0.651 ± 0.171\*\*\*   0.000                     0.464 ± 0.106\*\*\*     \<0.001                                     
  SMC of FFA            Placebo                                                                 0.699 ± 0.097\*\*\*   \<0.001               
  FRG                                                                   0.707 ± 0.087\*\*\*     \<0.001                                     

\* *p* *\<* 0.1.

\*\* *p \<* 0.05.

\*\*\* *p* \< 0.01.

ACTH, adrenocorticotropic hormone; DHEAS, dehydroepiandrosterone; E2, estradiol; FFA, free fatty acid; FRG, fermented red ginseng; FSH, follicle stimulating hormone; GC, glucocorticoid; GH, growth hormone; LH, luteinizing hormone; SE, standard error; SMC, squared multiple correlations ($\text{R}_{\text{smc}}^{2}$); T3, tri-iodothyronine; TSH, thyroid-stimulating hormone.

[^1]: ACTH; Adrenocorticotropic hormone, HGH; human growth hormone, DHEAS; Dehydroepiandrosterone, FFA; free fatty acid, FSH; follicle stimulating hormone , LH; luteinizing hormone, T3; triiodothyronine, TSH; thyroid-stimulating hormone.
